Taysha Gene Therapies price target lowered to $14 from $20 at Wells Fargo

Wells Fargo analyst Zachary Fadem lowered the firm’s price target on Taysha Gene Therapies to $14 from $20 and keeps an Overweight rating on the shares. The analyst notes Taysha Gene Therapies reported Q3 results on 11/8 and reiterated timing of upcoming events including the data readout for adult patients in cohort 1 with Rett Syndrome, initiation of a phase 1/2 trial in pediatric patients with Rett Syndrome, update on the regulatory pathway for TSHA-120 in GAN as well as comments on manufacturing.